Dec 30 (Reuters) - Verastem Inc VSTM.O:
VERASTEM ONCOLOGY ANNOUNCES FDA ACCEPTANCE AND PRIORITY REVIEW OF NEW DRUG APPLICATION FOR AVUTOMETINIB IN COMBINATION WITH DEFACTINIB FOR THE TREATMENT OF RECURRENT KRAS MUTANT LOW-GRADE SEROUS OVARIAN CANCER
VERASTEM INC - PDUFA TARGET ACTION DATE SET FOR JUNE 30, 2025
Source text: ID:nBwBJ6h5a
Further company coverage: VSTM.O
((Reuters.Briefs@thomsonreuters.com;))